A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.

Trial Details

NCT ID
NCT07110571
Phase
PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Adebrelimab Injection
  • SHR-A1811 for Injection
  • SHR-A1904 for Injection
  • SHR-8068 Injection
Locations (sample)
  • Shijiazhuang, Hebei, China|38.04139,114.47861
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients with histologically confirmed gastric or gastroesophageal junction adenocarcinoma who have not received prior anti-tumor therapy for gastr…
  • Age: ≥18 and ≤70 years, both male and female.
  • Ability to provide fresh tumor tissue (preferred) or archival formalin-fixed paraffin-embedded (FFPE) tumor blocks/unstained slides obtained within…
  • Availability of biomarker testing results before enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →